Rimon is proud to have acted as US counsel to Bionomics Limited, an Australian clinical-stage biotechnology company, on its re-domiciliation to the United States and the successful listing of its new Delaware parent company (Neuphoria Therapeutics Inc.) on Nasdaq. Such a re-domiciliation involves an Australian statutory scheme of arrangement under which, following approval by shareholders...The post Rimon advises Aussie biotech on re-domiciliation and listing on Nasdaq as a Delaware company appeared first on Rimon Law.
